Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmaceutical Science
Link
https://link.springer.com/content/pdf/10.1208/s12248-022-00710-4.pdf
Reference15 articles.
1. Al-Huniti N, Feng Y, Yu JJ, Lu Z, Nagase M, Zhou D, et al. Tumor growth dynamic modeling in oncology drug development and regulatory approval: past, present, and future opportunities. CPT Pharmacometrics Syst Pharmacol. 2020;9(8):419–27. https://doi.org/10.1002/psp4.12542.
2. Bruno R, Bottino D, de Alwis DP, Fojo AT, Guedj J, Liu C, et al. Progress and opportunities to advance clinical cancer therapeutics using tumor dynamic models. Clin Cancer Res. 2020;26(8):1787–95. https://doi.org/10.1158/1078-0432.CCR-19-0287.
3. Yin A, Moes D, van Hasselt JGC, Swen JJ, Guchelaar HJ. A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacometrics Syst Pharmacol. 2019;8(10):720–37. https://doi.org/10.1002/psp4.12450.
4. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Figg WD, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res. 2011;17(4):907–17. https://doi.org/10.1158/1078-0432.CCR-10-1762.
5. Claret L, Jin JY, Ferte C, Winter H, Girish S, Stroh M, et al. A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics. Clin Cancer Res. 2018;24(14):3292–8. https://doi.org/10.1158/1078-0432.CCR-17-3662.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer;European Journal of Cancer;2024-08
2. Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL;JTO Clinical and Research Reports;2024-07
3. Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two‐stage approaches;CPT: Pharmacometrics & Systems Pharmacology;2024-04-17
4. Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302;CPT: Pharmacometrics & Systems Pharmacology;2023-12-21
5. Challenging the Norm: A Multidisciplinary Perspective on Intravenous to Subcutaneous Bridging Strategies for Biologics;Clinical Pharmacology & Therapeutics;2023-12-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3